Ahmad A. Tarhini

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Neurology, Oncology +14

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 439 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman et al. · Nature Medicine · 2021 · 430 citations

Medicine, Clinical Sciences, Oncology +15

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Ahmad A. Tarhini, Haris Zahoor, Yan Lin et al. · Journal for ImmunoTherapy of Cancer · 2015 · 390 citations · Full text

Life Sciences, Immunology, Oncology +17

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

F. Stephen Hodi, David F. McDermott, Uma N. M. Rao et al. · JAMA · 2014 · 355 citations

Medicine, Oncology, Pharmacotherapy +17